NEUROTROPHINS, THEIR RECEPTORS AND KI-67 IN HUMAN GH-SECRETING PITUITARY ADENOMAS: AN IMMUNOHISTOCHEMICAL ANALYSIS

被引:9
作者
Artico, M. [1 ]
Bianchi, E. [1 ]
Magliulo, G. [1 ]
De Vincentiis, M. [1 ]
De Santis, E. [2 ]
Orlandi, A. [3 ]
Santoro, A. [4 ]
Pastore, F. S. [5 ]
Giangaspero, F. [6 ]
Caruso, R. [4 ]
Re, M. [7 ]
Fumagalli, L. [2 ]
机构
[1] Univ Rome Sapienza, Dept Sensory Organs, I-00161 Rome, Italy
[2] Univ Rome Sapienza, Dept Anat Histol Forens & Locomotor Syst Sci, I-00161 Rome, Italy
[3] Univ Roma Tor Vergata, Chair Pathol, Rome, Italy
[4] Univ Rome Sapienza, Dept Neurol Sci, I-00161 Rome, Italy
[5] Univ Roma Tor Vergata, Div Neurosurg, Rome, Italy
[6] IRCCS Neuromed, Pozzilli, Is, Italy
[7] Polytech Univ Marche, Dept Clin Sci, Ancona, Italy
关键词
pituitary gland; adenoma; neurotrophins; Ki-67; immunohistochemistry; NERVE GROWTH-FACTOR; ANTERIOR-PITUITARY; PATHOGENESIS; CELLS; IMMUNOREACTIVITY; FAMILY; GLAND; RAT;
D O I
10.1177/039463201202500114
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pituitary adenomas are a diverse group of tumors arising from the pituitary gland. Typically, they are small, slow-growing, hormonally inactive lesions that come to light as incidental findings on radiologic or postmortem examinations, although some small, slow-growing lesions with excessive hormonal activity may manifest with a clinical syndrome. The family of neurotrophins plays a key role in the development and maintenance of the pituitary endocrine cell function and in the regulation of hypothalamo-pituitary-adrenocortical axis activity. The objective of our experimental study is to investigate the localization of the neurotrophins, their relative receptors and to detect the expression level of Ki-67 to determine whether all these factors participate in the transformation and development of human pituitary adenomas. A very strong expression of Neurotrophin-3 (NT-3) and its receptor TrKC was observed in the extracellular matrix (ECM) and vessel endothelium, together with a clear/marked presence of Brain-derived neurotrophic factor (BDNF), and its receptor TrKB, thus confirming their direct involvement in the progression of pituitary adenomas. On the contrary, NGF (Nerve growth factor) and its receptor TrKA and p75NTR were weakly expressed in the epithelial gland cells and the ECM.
引用
收藏
页码:117 / 125
页数:9
相关论文
共 32 条
[1]   Trk neurotrophin receptor family immunoreactivity in rat and human pituitary tissues [J].
Aguado, F ;
Majó, G ;
de Aranda, IG ;
Ferrer, I .
NEUROSCIENCE LETTERS, 1998, 243 (1-3) :13-16
[2]   The pathogenesis of pituitary tumours [J].
Asa, SL ;
Ezzat, S .
NATURE REVIEWS CANCER, 2002, 2 (11) :836-849
[3]  
Asa SL, 1998, ATLAS TUMOR PATHOL, P1
[4]   The Pathogenesis of Pituitary Tumors [J].
Asa, Sylvia L. ;
Ezzat, Shereen .
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2009, 4 :97-126
[5]   P75NTR and TrkC neurotrophin receptors demonstrate a different immunoreactivity profile in comparison to TrkA and TrkB receptors in human normal pituitary gland and adenomas [J].
Assimakopoulou, Martha ;
Zolota, Vassiliki ;
Chondrogianni, Christina ;
Gatzounis, George ;
Varakis, John .
NEUROENDOCRINOLOGY, 2008, 88 (02) :127-134
[6]   THE TRK FAMILY OF NEUROTROPHIN RECEPTORS [J].
BARBACID, M .
JOURNAL OF NEUROBIOLOGY, 1994, 25 (11) :1386-1403
[7]   MICROADENOMAS OF THE PITUITARY AND ABNORMAL SELLAR TOMOGRAMS IN AN UNSELECTED AUTOPSY SERIES [J].
BURROW, GN ;
WORTZMAN, G ;
REWCASTLE, NB ;
HOLGATE, RC ;
KOVACS, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (03) :156-158
[8]   The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas [J].
Ekramullah, SM ;
Saitoh, Y ;
Arita, N ;
Ohnishi, T ;
Hayakawa, T .
ACTA NEUROCHIRURGICA, 1996, 138 (12) :1449-1455
[9]   The prevalence of pituitary adenomas - A systematic review [J].
Ezzat, S ;
Asa, SL ;
Couldwell, WT ;
Barr, CE ;
Dodge, WE ;
Vance, ML ;
McCutcheon, IE .
CANCER, 2004, 101 (03) :613-619
[10]   Editorial: Pituitary tumor pathogenesis - The hunt for novel candidate genes continues [J].
Ezzat, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11) :5116-5118